Entrada Therapeutics, Inc.

Contributing Author

Recent Articles by Entrada Therapeutics, Inc.

Jun-03	Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors TRDA GlobeNewswire
Jun-02	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TRDA GlobeNewswire
May-28	Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping TRDA GlobeNewswire
May-08	Entrada Therapeutics Reports First Quarter 2025 Financial Results TRDA GlobeNewswire